Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli’s potential in wet AMD and forecasting $1.5 billion peak sales.
Latest Ratings for OCUL
DateFirmActionFromTo Mar 2022JMP SecuritiesMaintainsMarket Outperform Nov 2021JMP SecuritiesMaintainsMarket Outperform Oct 2021HC Wainwright & Co.MaintainsBuy